Lamia Y. K. Haque, MD, MPH
Assistant Professor of Medicine (Digestive Diseases)Cards
About
Research
Publications
2025
Hepatology clinician readiness to provide addiction treatment in hepatology clinics: A mixed-methods formative evaluation
Haque L, Choi H, Justen M, Deng Y, Edelman E, Fiellin D. Hepatology clinician readiness to provide addiction treatment in hepatology clinics: A mixed-methods formative evaluation. Hepatology Communications 2025, 9: e0818. PMID: 41085538, PMCID: PMC12520222, DOI: 10.1097/hc9.0000000000000818.Peer-Reviewed Original ResearchReducing alcohol-associated liver disease burden in the general population
Asrani S, Mellinger J, Sterling S, Lucey M, Bradley K, Bhala N, Bray J, Chen P, DiMartini A, Fernandez A, Ghadiali M, Haque L, Khalili M, Lee B, Lin L, Pillai A, Satre D, Sengupta S, Serper M, Simonetto D, Thiele M, Welsh J, Wu T, Zsohar J, Shah V. Reducing alcohol-associated liver disease burden in the general population. The Lancet Gastroenterology & Hepatology 2025, 10: 1117-1131. PMID: 40976252, PMCID: PMC13277881, DOI: 10.1016/s2468-1253(25)00193-1.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConcomitant treatment of alcohol associated liver disease and alcohol use disorder in the nontransplant setting: A scoping review
Fathma S, McKee S, Grimshaw A, Boateng S, Fiellin D, Haque L, Mehal W, Banini B. Concomitant treatment of alcohol associated liver disease and alcohol use disorder in the nontransplant setting: A scoping review. Alcohol Clinical And Experimental Research 2025, 49: 1631-1639. PMID: 40650432, DOI: 10.1111/acer.70112.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMedications for Weight Loss and MASLD: A National Survey of Hepatology and Gastroenterology Provider Practices, Attitudes, and Knowledge Before Resmetirom
Im G, Asgharpour A, Aby E, Stine J, Mellinger J, Luther J, Izzy M, Haque L, Lee B, Cotter T, Sherman C, Jophlin L, Goel A, Rice J, Chandna S, Lizaola-Mayo B, Chen P, Singal A, Bansal M. Medications for Weight Loss and MASLD: A National Survey of Hepatology and Gastroenterology Provider Practices, Attitudes, and Knowledge Before Resmetirom. Journal Of Clinical Gastroenterology 2025, 10.1097/mcg.0000000000002147. PMID: 40549581, PMCID: PMC12312645, DOI: 10.1097/mcg.0000000000002147.Peer-Reviewed Original Research
2024
Using Phosphatidylethanol as an Adjunct to Self-Reported Alcohol Use Improves Identification of Liver Fibrosis Risk
Murnane P, Afshar M, Chamie G, Cook R, Ferguson T, Haque L, Jacobson K, Justice A, Kim T, Khalili M, Krupitsky E, McGinnis K, Molina P, Muyindike W, Myers B, Richards V, So-Armah K, Stewart S, Sulkowski M, Tien P, Hahn J. Using Phosphatidylethanol as an Adjunct to Self-Reported Alcohol Use Improves Identification of Liver Fibrosis Risk. The American Journal Of Gastroenterology 2024, 120: 1567-1575. PMID: 39480054, PMCID: PMC12041314, DOI: 10.14309/ajg.0000000000003178.Peer-Reviewed Original ResearchA Validated Algorithm to Identify Hepatic Decompensation in the Veterans Health Administration Electronic Health Record System
Haque L, Tate J, Chew M, Caniglia E, Taddei T, Re V. A Validated Algorithm to Identify Hepatic Decompensation in the Veterans Health Administration Electronic Health Record System. Pharmacoepidemiology And Drug Safety 2024, 33: e70024-e70024. PMID: 39477692, PMCID: PMC11631147, DOI: 10.1002/pds.70024.Peer-Reviewed Original ResearchEpidemiology and Health Care Burden of Alcohol Use Disorder
Choi H, Balter D, Haque L. Epidemiology and Health Care Burden of Alcohol Use Disorder. Clinics In Liver Disease 2024, 28: 577-588. PMID: 39362708, PMCID: PMC11772009, DOI: 10.1016/j.cld.2024.06.006.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsIntegrated and collaborative care across the spectrum of alcohol-associated liver disease and alcohol use disorder
Haque L, Leggio L. Integrated and collaborative care across the spectrum of alcohol-associated liver disease and alcohol use disorder. Hepatology 2024, 80: 1408-1423. PMID: 38935926, PMCID: PMC11841743, DOI: 10.1097/hep.0000000000000996.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsAddiction and liver disease series
Haque L, Mellinger J. Addiction and liver disease series. Clinical Liver Disease 2024, 23: e0227. PMCID: PMC11164010, DOI: 10.1097/cld.0000000000000227.Peer-Reviewed Original ResearchOpportunities for Alcohol-Related Care in the COVID-19 Pandemic and Beyond
Oldfield B, Haque L, Jennifer Edelman E. Opportunities for Alcohol-Related Care in the COVID-19 Pandemic and Beyond. Journal Of General Internal Medicine 2024, 39: 2129-2130. PMID: 38671202, PMCID: PMC11347542, DOI: 10.1007/s11606-024-08730-w.Peer-Reviewed Original Research
Academic Achievements & Community Involvement
Clinical Care
Overview
Lamia Haque, MD, MPH is a hepatologist (liver specialist) and addiction medicine physician who treats patients with liver diseases and co-occurring substance use disorders. She has additional training in transplant hepatology.
Dr. Haque says she was initially drawn to general internal medicine during medical school. “But after doing a few rotations with the hepatology service during residency at Yale, I felt it was a great fit. I became interested in the overlap between addiction and liver diseases, so I completed a fellowship in addiction medicine prior to my training in hepatology with the goal of integrating these skills into my work as a liver specialist,” she says.
“The main focus of my clinic is providing integrated care for patients who have both addiction and liver disease, particularly those with alcohol-associated liver disease and cirrhosis,” she says. “I find taking care of my patients to be very rewarding. You get to build a strong relationship over time.”
Because liver disease can be silent in its early stages, it can sometimes take patients by surprise if an abnormality shows up in their blood work or imaging.
“For patients with advanced liver disease and addiction, my work involves a lot of education and goal-setting. We work together to fine-tune medications, manage any complications that may arise, ensure that health maintenance measures are taken, determine the goals of care, and if indicated, set up a referral for a liver transplant evaluation,” says Dr. Haque. “Providing on-site addiction treatment and facilitating referrals as needed is an important part of delivering comprehensive care for patients with conditions such as alcohol-associated liver disease and alcohol use disorder.”
Dr. Haque’s research involves using implementation science methods to integrate evidence-based addiction treatment into liver care settings.
Clinical Specialties
Fact Sheets
Alcohol-related Liver Disease
Learn More on Yale MedicineRectal Bleeding
Learn More on Yale Medicine
Board Certifications
Obesity Medicine
- Certification Organization
- AB of Obesity Medicine
- Original Certification Date
- 2020
Addiction Medicine (Preventive Medicine)
- Certification Organization
- AB of Preventive Medicine
- Original Certification Date
- 2018
Yale Medicine News
News
News
Get In Touch
Contacts
Yale School of Medicine
Department of Medicine (Digestive Diseases), PO Box 208019
New Haven, CT 06520-8019
United States
Administrative Support
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
Events
Everyone Lamia Y. K. Haque, MD, MPHOnline registration will close at 1 pm the day of the webinar and the Zoom webinar link will be forwarded to registrants at that time.